The control of leishmaniases
Abstract
Human leishmaniases are caused by at least 13 different species and subspecies of parasite of the genus Leishmania. These parasites are transmitted to man from other infected persons or mammals by sandflies when taking a blood meal. Leishmaniases have been reported from about 80 countries and probably some 400 000 new cases occur each year. Clinically the leishmaniases can be divided into three major groups: visceral leishmaniases, which are usually fatal if untreated; cutaneous leishmaniases, which often produce permanent facial disfigurement; and mucocutaneous leishmaniasis of the New World, which produces severe mutilation by destruction of the naso-oro-pharyngeal cavity and sometimes death. Since the various forms of leishmaniasis differ substantially from each other in their epidemiology, the strategy for control must be adapted to the local situation in each endemic area, after thorough ecological and epidemiological studies of the vectors, the hosts, and the landscape. If insufficient baseline information is available, failure of haphazardly applied control measures can be expected. Peridomestic insecticide spraying together with treatment of patients is effective in certain foci of anthroponotic cutaneous leishmaniasis, urban visceral leishmaniasis, and uta. Extensive programmes to eradicate desert rodents, combined with land reclamation, resulted in a considerable decrease in the incidence of zoonotic cutaneous leishmaniasis in vast areas of the USSR. Since control of zoonotic cutaneous/mucocutaneous leishmaniasis of the New World is hardly feasible at present, the only rational approach to prevent some of mucosal lesions is early diagnosis and radical treatment of patients with the rather unsatisfactory drugs at present available.
Similar articles
-
Human leishmaniases: epidemiology and public health aspects.World Health Stat Q. 1992;45(2-3):267-75. World Health Stat Q. 1992. PMID: 1462660
-
Situational analysis of leishmaniases research in Kenya.Afr J Health Sci. 2006 Jan-Jun;13(1-2):7-21. Afr J Health Sci. 2006. PMID: 17348738
-
The current status of zoonotic leishmaniases and approaches to disease control.Int J Parasitol. 2005 Oct;35(11-12):1169-80. doi: 10.1016/j.ijpara.2005.07.001. Int J Parasitol. 2005. PMID: 16162348 Review.
-
Control of the leishmaniases. Report of a WHO Expert Committee.World Health Organ Tech Rep Ser. 1990;793:1-158. World Health Organ Tech Rep Ser. 1990. PMID: 2124015 No abstract available.
-
Vectors of leishmaniases in Venezuela.Parassitologia. 1991 Dec;33 Suppl:229-36. Parassitologia. 1991. PMID: 1841212 Review.
Cited by
-
Evolution of the Quinoline Scaffold for the Treatment of Leishmaniasis: A Structural Perspective.Pharmaceuticals (Basel). 2024 Feb 22;17(3):285. doi: 10.3390/ph17030285. Pharmaceuticals (Basel). 2024. PMID: 38543071 Free PMC article. Review.
-
The Glycosylphosphatidylinositol Anchor: A Linchpin for Cell Surface Versatility of Trypanosomatids.Front Cell Dev Biol. 2021 Nov 1;9:720536. doi: 10.3389/fcell.2021.720536. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34790656 Free PMC article. Review.
-
Amentoflavone as an Ally in the Treatment of Cutaneous Leishmaniasis: Analysis of Its Antioxidant/Prooxidant Mechanisms.Front Cell Infect Microbiol. 2021 Feb 25;11:615814. doi: 10.3389/fcimb.2021.615814. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 33718267 Free PMC article.
-
Recurrent kala-azar: report of two cured cases after total splenectomy.Rev Inst Med Trop Sao Paulo. 2020;62:e31. doi: 10.1590/s1678-9946202062031. Epub 2020 May 29. Rev Inst Med Trop Sao Paulo. 2020. PMID: 32491143 Free PMC article.
-
Multiple Relapses of Visceral Leishmaniasis in HIV Co-Infected Patients: A Case Series from Ethiopia.Curr Ther Res Clin Exp. 2020 Apr 8;92:100583. doi: 10.1016/j.curtheres.2020.100583. eCollection 2020. Curr Ther Res Clin Exp. 2020. PMID: 32382359 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical